Literature DB >> 8396095

Selection of dose regimens of azithromycin .

G Foulds1, R B Johnson.   

Abstract

The unique pharmacokinetics of azithromycin are characterized by high, sustained tissue concentrations. The concentrations of azithromycin were predicted, following various multiple dose regimens, from concentrations in tonsillar, prostatic, and uterine tissues following single oral doses. Following a five-day treatment regimen (500 mg on day 1, followed by 250 mg on days 2-5), or a three-day regimen (500 mg daily for three days), concentrations of azithromycin in tonsillar tissue, representative of respiratory tract tissues, will continuously be greater than the MICs for key target pathogens (Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus) in infections of the respiratory tract for up to 10 days. Since tissue concentrations above the MICs for infecting organisms were correlated with efficacy in animal models of infection, short treatment regimens consisting of once-daily oral administration of azithromycin should be effective in the treatment of a variety of infections. A single 1 g oral dose will provide concentrations in the uterus and prostate, representing urogenital tissues, above the MIC for Chlamydia trachomatis for approximately 10 days. Thus, this regimen should be effective in the treatment of chlamydial infections of the genital tract.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396095     DOI: 10.1093/jac/31.suppl_e.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen.

Authors:  Ping Liu; Hameed Allaudeen; Richa Chandra; Kem Phillips; Arvid Jungnik; Jeanne D Breen; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  Mechanistic study of the azithromycin dosage-form-dependent food effect.

Authors:  William Curatolo; George Foulds; Robert Labadie
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 4.  Interdisciplinary science and the design of a single-dose antibiotic therapy.

Authors:  William Curatolo
Journal:  Pharm Res       Date:  2011-02-11       Impact factor: 4.200

5.  Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients.

Authors:  Corrado Blandizzi; Tecla Malizia; Giovanna Batoni; Emilia Ghelardi; Fabio Baschiera; Paolo Bruschini; Sonia Senesi; Mario Campa; Mario Del Tacca
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 6.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.

Authors:  A M Worm; A Osterlind
Journal:  Genitourin Med       Date:  1995-08

8.  High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.

Authors:  Antonio Arrieta; Adriano Arguedas; Pilar Fernandez; Stan L Block; Paz Emperanza; Sergio L Vargas; William A Erhardt; Pascal J de Caprariis; Constance D Rothermel
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days.

Authors:  F Crokaert; A Hubloux; P Cauchie
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Authors:  C H Ballow; G W Amsden; V S Highet; A Forrest
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.